East Hampton, CT, United States of America

Ny Sin

USPTO Granted Patents = 28 (Patent Applications = 7)

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 14 (Patent Applications = 11)

Average Co-Inventor Count = 7.1

ph-index = 10

Forward Citations = 493(Granted Patents)

Location History:

Meriden, CT (US) (2002 - 2005)
East Hampton, CT (US) (2004 - 2020)
Wallingford, CT (US) (2018 - 2021)

Company Filing History:

21 out of 3,681

Bristol-myers Squibb Compnay

patents

3 out of 8

Viiv Healthcare UK (no. 4) Limited

patents

3 out of 42

Viiv Healthcare UK (no.5) Limited

Years Active: 2002-2021

Loading Chart...

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11084845 - C-3 and C-17 modified triterpenoids as HIV-1 inhibitors (2021-08-10),

2. 10780102 - Triterpenoids with HIV maturation inhibitory activity (2020-09-22),

3. 10421774 - C-3 and C-17 modified triterpenoids as HIV-1 inhibitors (2019-09-24),

4. 10245275 - Triterpenoids with HIV maturation inhibitory activity (2019-04-02),

5. 10047118 - C17-aryl substituted betulinic acid analogs (2018-08-14),

6. 9636375 - Hepatitis C virus inhibitors (2017-05-02),

7. 9527882 - Triterpenoids with HIV maturation inhibitory activity (2016-12-27),

8. 9227940 - Hepatitis C virus inhibitors (2016-01-05),

9. 8889871 - Hepatitis C virus inhibitors (2014-11-18),

10. 8889854 - C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity (2014-11-18),

11. 8846647 - C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity (2014-09-30),

12. 8802661 - C-28 amides of modified C-3 betulinic acid derivatives as HIV maturation inhibitors (2014-08-12),

13. 8754068 - Modified C-3 betulinic acid derivatives as HIV maturation inhibitors (2014-06-17),

14. 8710229 - Hepatitis C virus inhibitors (2014-04-29),

15. 8299094 - Hepatitis C virus inhibitors (2012-10-30),

Title: Innovations by Ny Sin in HIV Research

Introduction

Ny Sin, based in East Hampton, CT, is a prominent inventor in the field of pharmaceutical sciences. With an impressive portfolio of 28 patents, his contributions, particularly in the development of compounds aimed at combating HIV, have been significant in advancing medical research and treatments.

Latest Patents

Among Ny Sin's latest patents are the C-3 and C-17 modified triterpenoids, which serve as HIV-1 inhibitors. These patents detail compounds that possess drug and bio-affecting properties, showcasing the pharmaceutical compositions and methods of use. Notably, betulinic acid derivatives are highlighted for their unique antiviral activity as HIV maturation inhibitors. Additionally, the triterpenoids described possess significant antiviral properties and have been formulated to aid in the treatment of HIV and AIDS.

Career Highlights

Ny Sin has enjoyed a successful career, contributing his expertise to well-known companies such as Bristol-Myers Squibb Company and ViiV Healthcare UK (No. 4) Limited. His work has been instrumental in creating advancements in antiviral therapies, particularly those aimed at HIV.

Collaborations

Throughout his career, Ny Sin has collaborated with distinguished professionals, including Sing-Yuen Sit and Nicholas A. Meanwell. These collaborations have not only enriched his research but have also led to the successful development of innovative compounds with potential therapeutic applications.

Conclusion

With a strong commitment to innovation in the field of medicinal chemistry, Ny Sin continues to make strides in HIV research. His extensive patents and collaborations reflect his dedication to developing effective treatments, ultimately contributing to the global effort to combat HIV and AIDS.

This text is generated by artificial intelligence and may not be accurate.